27891581|t|Antigen specificity determines anti-red blood cell IgG-Fc alloantibody glycosylation and thereby severity of haemolytic disease of the fetus and newborn
27891581|a|Haemolytic disease of the fetus and newborn (HDFN) is a severe disease in which fetal red blood cells (RBC) are destroyed by maternal anti-RBC IgG alloantibodies. HDFN is most often caused by anti-D but may also occur due to anti-K, -c - or -E. We recently found N-linked glycosylation of anti-D to be skewed towards low fucosylation, thereby increasing the affinity to IgG-Fc receptor IIIa and IIIb, which correlated with HDFN disease severity. Here, we analysed 230 pregnant women with anti-c, -E or -K alloantibodies from a prospective screening cohort and investigated the type of Fc-tail glycosylation of these antibodies in relation to the trigger of immunisation and pregnancy outcome. Anti-c, -E and -K show - independent of the event that had led to immunisation - a different kind of Fc-glycosylation compared to that of the total IgG fraction, but with less pronounced differences compared to anti-D. High Fc-galactosylation and sialylation of anti-c correlated with HDFN disease severity, while low anti-K Fc-fucosylation correlated with severe fetal anaemia. IgG-Fc glycosylation of anti-RBC antibodies is shaped depending on the antigen. These features influence their clinical potency and may therefore be used to predict severity and identify those needing treatment.
27891581	31	70	anti-red blood cell IgG-Fc alloantibody	T103	UMLS:C0003241
27891581	109	152	haemolytic disease of the fetus and newborn	T038	UMLS:C0014761
27891581	153	196	Haemolytic disease of the fetus and newborn	T038	UMLS:C0014761
27891581	198	202	HDFN	T038	UMLS:C0014761
27891581	216	223	disease	T038	UMLS:C0012634
27891581	233	238	fetal	T017	UMLS:C0015965
27891581	239	254	red blood cells	T017	UMLS:C0014792
27891581	256	259	RBC	T017	UMLS:C0014792
27891581	278	314	maternal anti-RBC IgG alloantibodies	T103	UMLS:C0729663
27891581	316	320	HDFN	T038	UMLS:C0014761
27891581	345	351	anti-D	T103	UMLS:C0140430
27891581	378	384	anti-K	T103	UMLS:C0313239
27891581	386	388	-c	T103	UMLS:C0432626
27891581	394	396	-E	T103	UMLS:C0947659
27891581	416	438	N-linked glycosylation	T038	UMLS:C1622430
27891581	442	448	anti-D	T103	UMLS:C0140430
27891581	474	486	fucosylation	T038	UMLS:C3271553
27891581	511	519	affinity	T038	UMLS:C0003255
27891581	523	543	IgG-Fc receptor IIIa	T103	UMLS:C1521898
27891581	548	552	IIIb	T103	UMLS:C0966831
27891581	576	580	HDFN	T038	UMLS:C0014761
27891581	581	588	disease	T038	UMLS:C0012634
27891581	621	635	pregnant women	T098	UMLS:C0033011
27891581	641	647	anti-c	T103	UMLS:C0432626
27891581	649	651	-E	T103	UMLS:C0947659
27891581	655	657	-K	T103	UMLS:C0313239
27891581	658	672	alloantibodies	T103	UMLS:C0022144
27891581	692	708	screening cohort	T058	UMLS:C0422390
27891581	738	759	Fc-tail glycosylation	T038	UMLS:C0376322
27891581	769	779	antibodies	T103	UMLS:C0003241
27891581	810	822	immunisation	T058	UMLS:C0020971
27891581	827	844	pregnancy outcome	T033	UMLS:C0032972
27891581	846	852	Anti-c	T103	UMLS:C0432626
27891581	854	856	-E	T103	UMLS:C0947659
27891581	861	863	-K	T103	UMLS:C0313239
27891581	912	924	immunisation	T058	UMLS:C0020971
27891581	947	963	Fc-glycosylation	T038	UMLS:C0376322
27891581	994	997	IgG	T103	UMLS:C0020852
27891581	994	1006	IgG fraction	T103	UMLS:C0020852
27891581	1057	1063	anti-D	T103	UMLS:C0140430
27891581	1070	1088	Fc-galactosylation	T038	UMLS:C1159287
27891581	1093	1104	sialylation	T038	UMLS:C4235385
27891581	1108	1114	anti-c	T103	UMLS:C0432626
27891581	1131	1135	HDFN	T038	UMLS:C0014761
27891581	1136	1143	disease	T038	UMLS:C0012634
27891581	1164	1170	anti-K	T103	UMLS:C0313239
27891581	1171	1186	Fc-fucosylation	T038	UMLS:C1159287
27891581	1210	1223	fetal anaemia	T038	UMLS:C2349595
27891581	1225	1245	IgG-Fc glycosylation	T038	UMLS:C0376322
27891581	1249	1268	anti-RBC antibodies	T103	UMLS:C0003241
27891581	1296	1303	antigen	T103	UMLS:C0003320